Patents by Inventor Terry J. Fry
Terry J. Fry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11980640Abstract: An embodiment of the invention provides bicistronic chimeric antigen receptor (CAR) amino acid constructs. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CAR constructs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed. Methods of making the CAR constructs are disclosed.Type: GrantFiled: May 15, 2018Date of Patent: May 14, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Haiying Qin, Crystal L Mackall, Terry J. Fry
-
Patent number: 11965022Abstract: Disclosed herein are engineered cells and/or hypoimmunogenic cells including engineered and/or hypoimmunogenic stem cells, engineered and/or hypoimmunogenic cells differentiated therefrom, engineered and/or hypoimmunogenic CAR-T cells (primary or differentiated from engineered and/or hypoimmunogenic stem cells) and related methods of their use and generation. Provided herein are engineered and/or hypoimmunogenic cells exhibiting reduced expression of MHC class I and/or MHC class II human leukocyte antigens and T-cell receptors. In some embodiments, such cells also exogenously express one or more tolerogenic factors such as CD47 and one or more chimeric antigen receptors (CAR)s.Type: GrantFiled: December 23, 2021Date of Patent: April 23, 2024Assignee: Sana Biotechnology, Inc.Inventors: Sonja Schrepfer, Lindong Weng, Terry J. Fry
-
Patent number: 11939377Abstract: An affinity matured anti-CD22 human monoclonal antibody exhibiting significantly higher affinity (less than 50 pM) compared to the parental antibody (affinity of about 2 nM) is described. The anti-CD22 variant antibody or a fragment thereof, such as a single-chain variable fragment (scFv), can be used as the antigen-binding portion of chimeric antigen receptors (CARs), antibody-drug conjugates (ADCs), immunotoxins or multi-specific antibodies for the treatment of B-cell malignancies.Type: GrantFiled: July 11, 2019Date of Patent: March 26, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Zhongyu Zhu, Sneha Ramakrishna, Terry J. Fry
-
Publication number: 20240002507Abstract: Disclosed herein are engineered cells and/or hypoimmunogenic cells including engineered and/or hypoimmunogenic stem cells, engineered and/or hypoimmunogenic cells differentiated therefrom, engineered and/or hypoimmunogenic CAR-T cells (primary or differentiated from engineered and/or hypoimmunogenic stem cells) and related methods of their use and generation. Provided herein are engineered and/or hypoimmunogenic cells exhibiting reduced expression of MHC class I and/or MHC class II human leukocyte antigens and T-cell receptors. In some embodiments, such cells also exogenously express one or more tolerogenic factors such as CD47 and one or more chimeric antigen receptors (CAR)s.Type: ApplicationFiled: June 21, 2023Publication date: January 4, 2024Inventors: Sonja Schrepfer, Lindong Weng, Terry J. Fry
-
Patent number: 11834509Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain specific for TSLPR, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of a proliferative disorder, e.g., cancer, in a mammal and methods of treating or preventing a proliferative disorder, e.g., cancer, in a mammal are also disclosed.Type: GrantFiled: April 28, 2020Date of Patent: December 5, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Haiying Qin, Terry J. Fry
-
Patent number: 11802157Abstract: Disclosed herein are engineered cells and/or hypoimmunogenic cells including engineered and/or hypoimmunogenic stem cells, engineered and/or hypoimmunogenic cells differentiated therefrom, engineered and/or hypoimmunogenic CAR-T cells (primary or differentiated from engineered and/or hypoimmunogenic stem cells) and related methods of their use and generation. Provided herein are engineered and/or hypoimmunogenic cells exhibiting reduced expression of MHC class I and/or MHC class II human leukocyte antigens and T-cell receptors. In some embodiments, such cells also exogenously express one or more tolerogenic factors such as CD47 and one or more chimeric antigen receptors (CAR)s.Type: GrantFiled: February 7, 2022Date of Patent: October 31, 2023Assignee: Sana Biotechnology, Inc.Inventors: Sonja Schrepfer, Lindong Weng, Terry J. Fry
-
Publication number: 20230174614Abstract: The present disclosure provides multispecific chimeric antigen receptors (CARs) having antigenic specificity for FLT3 and CD19, FLT3 and CD22, FLT3 and CD123 or FLT3 and CD33. Nucleic acids, expression constructs, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the multispecific CARs are disclosed. Methods of treating or preventing ALL, AML and/or other forms of cancer in a mammal are also disclosed.Type: ApplicationFiled: April 30, 2021Publication date: June 8, 2023Inventor: Terry J. FRY
-
Publication number: 20220331358Abstract: Disclosed herein are engineered cells and/or hypoimmunogenic cells including engineered and/or hypoimmunogenic stem cells, engineered and/or hypoimmunogenic cells differentiated therefrom, engineered and/or hypoimmunogenic CAR-T cells (primary or differentiated from engineered and/or hypoimmunogenic stem cells) and related methods of their use and generation. Provided herein are engineered and/or hypoimmunogenic cells exhibiting reduced expression of MHC class I and/or MHC class II human leukocyte antigens and T-cell receptors. In some embodiments, such cells also exogenously express one or more tolerogenic factors such as CD47 and one or more chimeric antigen receptors (CAR)s.Type: ApplicationFiled: December 23, 2021Publication date: October 20, 2022Inventors: Sonja Schrepfer, Lindong Weng, Terry J. Fry
-
Publication number: 20220259317Abstract: An embodiment of the invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain specific for FLT3, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of a proliferative disorder, e.g., cancer, in a mammal and methods of treating or preventing a proliferative disorder, e.g., cancer, in a mammal are also disclosed.Type: ApplicationFiled: March 8, 2022Publication date: August 18, 2022Applicant: The United States of America,as represented by the Secretary, Dept. of Health and Human ServicesInventors: Christopher D. Chien, Terry J. Fry
-
Publication number: 20220227865Abstract: Disclosed herein are engineered cells and/or hypoimmunogenic cells including engineered and/or hypoimmunogenic stem cells, engineered and/or hypoimmunogenic cells differentiated therefrom, engineered and/or hypoimmunogenic CAR-T cells (primary or differentiated from engineered and/or hypoimmunogenic stem cells) and related methods of their use and generation. Provided herein are engineered and/or hypoimmunogenic cells exhibiting reduced expression of MHC class I and/or MHC class II human leukocyte antigens and T-cell receptors. In some embodiments, such cells also exogenously express one or more tolerogenic factors such as CD47 and one or more chimeric antigen receptors (CAR)s.Type: ApplicationFiled: February 7, 2022Publication date: July 21, 2022Inventors: Sonja Schrepfer, Lindong Weng, Terry J. Fry
-
Publication number: 20220127367Abstract: Human monoclonal antibodies that specifically bind Fms-like tyrosine kinase 3 (FLT3) are described. Chimeric antigen receptors (CARs) and other antibody conjugates that include the FLT3-specific monoclonal antibodies are also described. Methods for the diagnosis and treatment of FLT3-associated cancer, such as acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML), are further described.Type: ApplicationFiled: January 6, 2022Publication date: April 28, 2022Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Weizao Chen, Terry J. Fry, Christopher Chien
-
Patent number: 11299546Abstract: An embodiment of the invention provides a chimeric antigen receptor (C AR) comprising an antigen binding domain specific for FLT3, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of a proliferative disorder, e.g., cancer, in a mammal and methods of treating or preventing a proliferative disorder, e.g., cancer, in a mammal are also disclosed.Type: GrantFiled: May 26, 2017Date of Patent: April 12, 2022Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Christopher D. Chien, Terry J. Fry
-
Patent number: 11236171Abstract: Human monoclonal antibodies that specifically bind Fms-like tyrosine kinase 3 (FLT3) are described. Chimeric antigen receptors (CARs) and other antibody conjugates that include the FLT3-specific monoclonal antibodies are also described. Methods for the diagnosis and treatment of FLT3-associated cancer, such as acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML), are further described.Type: GrantFiled: December 21, 2017Date of Patent: February 1, 2022Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Weizao Chen, Terry J. Fry, Christopher Chien, Haiying Qin
-
Publication number: 20210324074Abstract: An affinity matured anti-CD22 human monoclonal antibody exhibiting significantly higher affinity (less than 50 pM) compared to the parental antibody (affinity of about 2 nM) is described. The anti-CD22 variant antibody or a fragment thereof, such as a single-chain variable fragment (scFv), can be used as the antigen-binding portion of chimeric antigen receptors (CARs), antibody-drug conjugates (ADCs), immunotoxins or multi-specific antibodies for the treatment of B-cell malignancies.Type: ApplicationFiled: July 11, 2019Publication date: October 21, 2021Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Zhongyu Zhu, Sneha Ramakrishna, Terry J. Fry
-
Publication number: 20210017277Abstract: Embodiments of the invention provide chimeric antigen receptors (CARs) having antigenic specificity for CD33. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: ApplicationFiled: March 14, 2019Publication date: January 21, 2021Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Haiying Qin, Terry J. Fry
-
Publication number: 20200308289Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain specific for TSLPR, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of a proliferative disorder, e.g., cancer, in a mammal and methods of treating or preventing a proliferative disorder, e.g., cancer, in a mammal are also disclosed.Type: ApplicationFiled: April 28, 2020Publication date: October 1, 2020Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Haiying Qin, Terry J. Fry
-
Patent number: 10738116Abstract: The invention provides dual specific chimeric antigen receptors (CARs) having antigenic specificity for CD19 and CD22. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: GrantFiled: March 18, 2016Date of Patent: August 11, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Terry J. Fry, Crystal L. Mackall, Rimas J. Orentas, Waleed Haso, Haiying Qin
-
Patent number: 10676528Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain specific for TSLPR, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of a proliferative disorder, e.g., cancer, in a mammal and methods of treating or preventing a proliferative disorder, e.g., cancer, in a mammal are also disclosed.Type: GrantFiled: October 30, 2014Date of Patent: June 9, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Haiying Qin, Terry J. Fry
-
Publication number: 20200147134Abstract: An embodiment of the invention provides bicistronic chimeric antigen receptor (CAR) amino acid constructs. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CAR constructs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed. Methods of making the CAR constructs are disclosed.Type: ApplicationFiled: May 15, 2018Publication date: May 14, 2020Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Haiying Qin, Crystal L. Mackall, Terry J. Fry
-
Publication number: 20190352408Abstract: Human monoclonal antibodies that specifically bind Fms-like tyrosine kinase 3 (FLT3) are described. Chimeric antigen receptors (CARs) and other antibody conjugates that include the FLT3-specific monoclonal antibodies are also described. Methods for the diagnosis and treatment of FLT3-associated cancer, such as acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML), are further described.Type: ApplicationFiled: December 21, 2017Publication date: November 21, 2019Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Weizao Chen, Terry J. Fry, Christopher Chien